Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Glyburide

FDA-approved product (tablet, oral), marketed as Diabeta, Glyburide, Glyburide (Micronized) and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Glyburide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas
FDA pharmacologic class
Sulfonylurea FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Glyburide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Glyburide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

    NCT05751525 · start 2016-07-01

    Registered record
    Registry ID
    NCT05751525
    Conditions
    Neurodevelopmental Disorders; Intellectual Disability; Development Delay; ADHD; Autism Spectrum Disorder; Epilepsy
    Interventions
    Sulfonylurea
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-07-01
    Completion
    2025-12-31
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurodevelopmental Disorders; Intellectual Disability; Development Delay; ADHD +2 more
    InterventionSulfonylurea
    PhaseNot recorded
    Registry statusUnknown

  • Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

    NCT02624817 · start 2015-12

    Registered record
    Registry ID
    NCT02624817
    Conditions
    Permanent Neonatal Diabetes Mellitus
    Interventions
    Sulfonylurea
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPermanent Neonatal Diabetes Mellitus
    InterventionSulfonylurea
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

    NCT02318693 · start 2015-02-04

    Registered record
    Registry ID
    NCT02318693
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin; Glibenclamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-04
    Completion
    2015-12-15
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin; Glibenclamide
    PhasePhase 4
    Registry statusCompleted

  • Sitagliptin and Endothelial Dysfunction

    NCT02406950 · start 2015-02

    Registered record
    Registry ID
    NCT02406950
    Conditions
    Healthy
    Interventions
    Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-02
    Completion
    2015-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSitagliptin
    PhasePhase 3
    Registry statusUnknown

  • Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

    NCT02201602 · start 2014-08

    Registered record
    Registry ID
    NCT02201602
    Conditions
    Diabetes
    Interventions
    Gliclazide; Glibenclamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-08
    Completion
    2016-07
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionGliclazide; Glibenclamide
    PhasePhase 4
    Registry statusCompleted

  • Incretin-based Drugs and Pancreatic Cancer

    NCT02475499 · start 2014-03

    Registered record
    Registry ID
    NCT02475499
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    DPP-4 inhibitors; GLP-1 analogs; Sulfonylureas; Biguanides; Thiazolidinediones; Alpha-glucosidase inhibitors; Meglitinides
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-04
    Enrolment
    886,172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionDPP-4 inhibitors; GLP-1 analogs; Sulfonylureas; Biguanides +3 more
    PhaseNot recorded
    Registry statusCompleted

  • Oral Antidiabetic Agents in Pregnancy

    NCT02091336 · start 2014-01

    Registered record
    Registry ID
    NCT02091336
    Conditions
    Gestational Diabetes
    Interventions
    Metformin; Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2016-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Diabetes
    InterventionMetformin; Glyburide
    PhasePhase 4
    Registry statusUnknown

  • forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

    NCT01944618 · start 2013-10

    Registered record
    Registry ID
    NCT01944618
    Conditions
    Type 2 Diabetes
    Interventions
    Forxiga
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2013-10
    Completion
    2015-10
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionForxiga
    PhaseNot recorded
    Registry statusTerminated

  • Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

    NCT02145611 · start 2013-07

    Registered record
    Registry ID
    NCT02145611
    Conditions
    Type 2 Diabetes Mellitus; Hypertension; Endothelial Dysfunction
    Interventions
    Glibenclamide; Vildagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-07
    Completion
    2016-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Hypertension; Endothelial Dysfunction
    InterventionGlibenclamide; Vildagliptin
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

    NCT01798706 · start 2013-06

    Registered record
    Registry ID
    NCT01798706
    Conditions
    Type 2 Diabetes
    Interventions
    Lixisenatide (AVE0010); Placebo; Antidiabetic background therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-02
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionLixisenatide (AVE0010); Placebo; Antidiabetic background therapy
    PhasePhase 3
    Registry statusCompleted

  • Glyburide Healthy Volunteer Study

    NCT01716338 · start 2013-01

    Registered record
    Registry ID
    NCT01716338
    Conditions
    Healthy Volunteers
    Interventions
    Glyburide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionGlyburide; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

    NCT01584232 · start 2012-04

    Registered record
    Registry ID
    NCT01584232
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    LY2189265; Insulin glargine; Sulfonylureas (SU); Biguanide (BG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2013-07
    Enrolment
    361

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionLY2189265; Insulin glargine; Sulfonylureas (SU); Biguanide (BG)
    PhasePhase 3
    Registry statusCompleted

  • Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)

    NCT01329016 · start 2011-07

    Registered record
    Registry ID
    NCT01329016
    Conditions
    Gestational Diabetes Mellitus
    Interventions
    Glyburide; Metformin; Glyburide-Metformin combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-07
    Completion
    2015-02-28
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Diabetes Mellitus
    InterventionGlyburide; Metformin; Glyburide-Metformin combination
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Glyburide Advantage in Malignant Edema and Stroke Pilot

    NCT01268683 · start 2011-05-26

    Registered record
    Registry ID
    NCT01268683
    Conditions
    Ischemic Stroke
    Interventions
    Glyburide for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-05-26
    Completion
    2012-06-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke
    InterventionGlyburide for Injection
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • R230C and C230C Variants of ABCA1 and Glyburide Response

    NCT01456650 · start 2011-03

    Registered record
    Registry ID
    NCT01456650
    Conditions
    Type 2 Diabetes
    Interventions
    Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-12
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionGlyburide
    PhasePhase 4
    Registry statusCompleted